|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of IL-7 and its receptor IL-7R in tumor tissues was also recovered by TCM.
|
31138762 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-7(IL-7) can regulate proliferation and apoptosis of cell and also regulate tumor lymphangiogenesis, but whether it regulating autophagy of tumor cells is not well known.
|
30362635 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-7 increased tumor sphere formation and expression of epithelial-mesenchymal transition (EMT) markers.
|
31061414 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, cisplatin significantly inhibited tumour growth and IL-7 combined with cisplatin achieved the best therapeutic effect.
|
31599032 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, IL-7 expression was significantly reduced in BALF from tumor site in squamous carcinoma patients, especially in stage III and IV.
|
30557823 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-7's involvement in neoplasia has been appreciated through studies of IL-7 transgenic (Tg) mice models and human lymphoma patients.
|
30373315 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In breast cancer (BC), IL-7 promotes growth of tumor cells in culture through the activation of JAK1/3-STAT5 and PI3K/AKT pathways, and expression of IL-7 signaling components was associated with worst prognosis.
|
28964592 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that fibroblasts expressing the Cre recombinase under the control of the interleukin 7 promoter occupied mainly the tumor margin where they physically interacted with tumor cells.
|
29632733 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, to protect our tumor-targeted cells from the elevated levels of immune-inhibitory cytokines present in the tumor milieu, we co-expressed an inverted cytokine receptor linking the IL4 receptor exodomain with the IL7 receptor endodomain (4/7ICR) in order to transform the suppressive IL4 signal into one that would enhance the anti-tumor effects of our CAR T cells at the tumor site.
|
29747685 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.
|
29505028 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using regulatory T (T<sub>reg</sub>)-cell-enriched mouse tumor model, we determine that M6PR<sup>high</sup> IL-2 effectors but not M6PR<sup>low</sup> IL-7 effectors adoptively transferred into tumors are vulnerable to T<sub>reg</sub> Gzm-B-mediated cell apoptosis.
|
28496990 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Disrupted fibroblastic reticular cells and interleukin-7 expression in tumor draining lymph nodes.
|
28928833 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review aims to summarize the role of IL-7 in immunity and its role in the pathogenesis of neoplasia.
|
28314253 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
|
28830878 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, our study is the first to demonstrate IL-7 elevation in CRC in association with metastatic disease and tumor location.
|
27866242 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that, in lung cancer cells xenograft tumors IL-7/IL-7 receptor (IL-7R) increase the expression of VEGF-D and lymphangiogenesis, induce c-Fos and c-Jun heterodimer formation, and enhance c-Fos/c-Jun DNA binding activity to regulate VEGF-D. Taken together, our results provided evidence that IL-7/IL-7R induce VEGF-D upregulation and promote lymphangiogenesis via c-Fos/c-Jun pathway in lung cancer.
|
24115038 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We generated a bicistronic retroviral vector encoding a GD2-specific CAR and the IL-7Rα subunit, expressed the genes in EBV-CTLs, and assessed their capacity to control tumor growth in the presence of Treg in vitro and in vivo when exposed to either interleukin-2 (IL-2) or IL-7 in a neuroblastoma xenograft.
|
24097874 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Members of 4 gene-sets were enriched among these 10 genes: (i) lung adenocarcinoma tumor-sequencing genes, (ii) IL-7 pathway genes, (iii) kidney cell response to arsenic, and (iv) CD4 T-cell responses.
|
25171373 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An HLA-dependent increase in CD137 expression was observed following incubation of fresh enzyme-digested tumor or ascites in IL-7 and IL-15 cytokines, but not IL-2.
|
24045181 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-7 inhibited tumor growth and prolonged the survival of tumor-bearing mice with corresponding increases in the frequency of CD4 and CD8 T cells, Th1 (CD4(+)IFN-γ(+)), Tc1 (CD8(+)IFN-γ(+)) and T cells cytolytic activity against Meth A cells.
|
24406503 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correlation analysis revealed significant positive correlations between tumor TL and peripheral levels of three cytokines (IL-7, IL-8 and IL-10).
|
23383336 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of transforming growth factor-β (TGF-β), osteoprotegerin (OPG), IL-7 and dickkopf-1 (DKK-1) was higher in primary tumors than in bone metastases.
|
23404437 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, the effect of IL-7 variants on tumor cell proliferation remains unclear.
|
22618230 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results establish that IL-7 contributes to the progression of human T-cell leukemia, and they offer preclinical validation of the concept that targeting IL-7/IL-7R signaling in the tumor microenvironment could elicit therapeutic effects in T-ALL.
|
21593192 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrated that utilizing nonlytic Fc-fused IL-7 (IL-7-Fc(m)) as a genetic adjuvant significantly enhanced not only CD4(+) but also CD8(+) T-cell responses by E7 DNA immunization, in addition to improving protection against TC-1-induced tumors in comparison to IL-7 alone.
|
19950168 |
2010 |